{"entity":{"id":"nct00833248","kind":"trial","name":"Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer","aka":[],"tldr":"A phase 3 trial of Degarelix, Goserelin / leuprolide and Bicalutamide in Prostate cancer, run by Ferring Pharmaceuticals, completed.","summary":"Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer is a phase 3 interventional study registered as NCT00833248 by Ferring Pharmaceuticals, with 246 participants recorded, started 2009-04 and reaching its primary completion in 2011-09. Interventions recorded: Degarelix, Goserelin, Bicalutamide. Conditions recorded: Prostate Cancer.\n\nLinked to the drug Degarelix because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT00833248","url":"https://clinicaltrials.gov/study/NCT00833248"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":["degarelix","goserelin","bicalutamide"],"companies":["ferring"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT00833248","phase":"3","setting":"A Randomised, Parallel Arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-high Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent)","sponsor":"Ferring Pharmaceuticals","started":"2009-04","yearReported":2012,"enrolled":246,"enrolledBasis":"registry","outcomes":[{"endpoint":"Change From Baseline in Prostate Size Based on Trans Rectal Ultra Sound (TRUS) at Week 12 (Full Analysis Set)","primary":true,"unit":"milliliter","arms":[{"name":"Degarelix 240 mg/80 mg","n":176,"value":-36,"note":"SD 14.5; Figures from the ClinicalTrials.gov results section (first posted 2012-09-27), not from a publication"},{"name":"Goserelin (3.6 mg) + Bicalutamide (50 mg)","n":62,"value":-35.3,"note":"SD 16.7"}],"p":"0.8942","source":"https://clinicaltrials.gov/study/NCT00833248?tab=results"}]},"route":"/trials/nct00833248/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"bicalutamide","kind":"drug","name":"Bicalutamide","route":"/drugs/bicalutamide/"},{"id":"degarelix","kind":"drug","name":"Degarelix","route":"/drugs/degarelix/"},{"id":"goserelin","kind":"drug","name":"Goserelin / leuprolide (ovarian function suppression)","route":"/drugs/goserelin/"}],"company":[{"id":"ferring","kind":"company","name":"Ferring Pharmaceuticals","route":"/companies/ferring/"}]}}